Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Virol J. 2022 Jan 4;19(1):2. doi: 10.1186/s12985-021-01737-3.
The current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inactivated vaccine and a heterologous mutant RBD vaccine, and then evaluated their neutralizing antibody responses against variants including Beta, Delta, Alpha, Iota, Kappa, and A.23.1. These data showed that a third booster dose of heterologous RBD vaccine especially after two doses of inactivated vaccines significantly enhanced the GMTs of nAbs against all SARS-CoV-2 variants we tested. In addition, the WT and variants all displayed good cross-immunogenicity and might be applied in the design of booster vaccines to induce broadly neutralizing antibodies.
当前由不断出现的 SARS-CoV-2 变体引起的 COVID-19 大流行仍然对全球公共卫生构成威胁。迫切需要有效的下一代疫苗和优化的加强针接种策略。在这里,我们依次用 SARS-CoV-2 野生型灭活疫苗和异源突变 RBD 疫苗对小鼠进行免疫,并评估了它们对包括 Beta、Delta、Alpha、Iota、Kappa 和 A.23.1 在内的变体的中和抗体反应。这些数据表明,异源 RBD 疫苗的第三剂加强针,特别是在两剂灭活疫苗之后,显著提高了对我们测试的所有 SARS-CoV-2 变体的 nAb 的 GMT。此外,WT 和变体均显示出良好的交叉免疫原性,可应用于加强针疫苗的设计,以诱导广泛中和抗体。